Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 18 of 18 for “"Myelodysplastic syndromes"”.
-
Dissecting The Mechanisms of Venetoclax Resistance In Myelodysplastic Syndromes
<p>Myelodysplastic syndromes (MDS) are a class of heterogeneous clonal hematopoietic disorders. The current standard of care for MDS is the hypomethylating agent (HMA)-based therapy. However, only 50 percent of the patients respond, with transient effects and no approved second-line treatment …
-
Biology of stem cells and myeloid progenitor cells in myelodysplastic syndromes.
Contains fulltext : 52863.pdf (Publisher’s version ) (Open Access)
-
Patients with lower-risk myelodysplastic syndromes: in scope of iron related complications
Contains fulltext : 203527.pdf (Publisher’s version ) (Open Access)
-
Targeting integrin alpha 5 and focal adhesion kinase to overcome azacitidine resistance in higher risk myelodysplastic syndromes
Myelodysplastic syndromes are typified by bone marrow failure due to profoundly impaired haematopoietic differentiation with higher risk disease commonly progressing to acute myeloid leukaemia. Azacitidine (AZA) and decitabine are the only available therapies for higher risk myelodysplastic …
-
Computational analyses of blood cells: somatic evolution and morphology
… that can progress to blood cancers such as myelodysplastic syndromes, characterized by an excess of abnormally developed (or dysplastic) cells in the bone marrow and in the blood. Blood cancers such as these are usually diagnosed by trained experts using a number of complementary analyses, …
-
PU.1-ACTIVATED GENOMIC REGIONS DEFINE LOW-RISK MDS SUBSETS CHARACTERIZED BY IMMUNE DYSREGULATION AND DISEASE PROGRESSION
Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms with an increased risk of progression to secondary acute myeloid leukemia (sAML). This study investigates the genomic signatures associated to disease progression in MDS. To this end, we profiled active genomic regulatory regions …
-
p53 acts to prevent the formation of pathological R-loops during epigenetic stress
… treatment of Acute Myeloid Leukaemia and some myelodysplastic syndromes. The two are frequently used interchangeably, surprisingly as their selectivity of de-methylation is unique from the other, however there remains very few studies which compare them directly. R-loops are three stranded …
-
Biological and Aetiological Inference from the Statistical Genetic Analyses of Blood Cell Traits
… as sepsis, Szary disease, toxic granulation, and myelodysplastic syndromes, or correlate with assessments of cell morphology from blood smear images. Here, I report the results of my genome- wide association study of 63 previously genetically unstudied blood cell flow cytometry phenotypes. I have …
-
Clinical Utility and Impact of Targeted Nucleic Acid Sequencing in Myeloid Malignancies and Precursor Lesions
… mutated in myeloid malignancies, including myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) and acute myeloid leukemia (AML), with expanding diagnostic and clinical significance. Given the breadth of genetic aberrations required to diagnose these diseases, higher …
-
Detection of Aneuploidy for Chromosomes 7 and 8 Using Fluorescence <i>In Situ</i> Hybridization in Patients with Aplastic Anemia and Sequencing of the Mitotic Checkpoint Gene hBUB1
… by complete bone marrow failure. Progression to myelodysplastic syndromes (MDS) and acute nonlymphocytic leukemia (ANLL) occurs frequently. At the time of transformation, cytogenetic abnormalities are common. Detection of cytogenetic abnormalities prior to leukemic transformation may indicate …
-
Trisomies in Hematologic Malignancies
… change in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and on high hyperdiploidy ? gains of multiple chromosomes ? in childhood acute lymphoblastic leukemia (ALL). In the first two articles, AML and MDS cases with +8 as the seemingly sole abnormality were studied with …
-
PATTERN OF INNATE IMMUNITY IN PATIENTS AFFECTED BY MYELODYSPLASTIC SYNDROME (MDS) EITHER BEFORE ANDAFTER HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Myelodysplastic syndromes (MDS) are a heterogenous group of myeloid neoplasms that primarily affect elderly people and, in the context of population aging, MDS incidence is set to increase substantially. MDS patients have a variable risk of progression to acute myeloid leukemia (AML) and are …
-
Mechanisms driving the expansion and progression of splicing factor-mutant clonal haematopoiesis
… mis-splicing events seen in SF3B1-mutant myelodysplastic syndromes (MDS). We then performed high-throughput drug screening to identify therapeutic vulnerabilities of SF3B1-mutant cells. Alongside this, we developed a pipeline for the collection of bone marrow aspirate samples from …
-
Assessing the psychosocial impact of monoclonal gammopathy of undetermined significance (MGUS)
… 62.1% of GPs/GP trainees with MM, lymphoma and myelodysplastic syndromes the most commonly reported cancers associated with MGUS. The need for MGUS focused information and education resources for GPs was also highlighted. <br/><br/>Data from the previous studies was triangulated to develop an …
-
Integration of class 1 HDAC inhibitors into current treatments for prostate cancer
… inhibitors (HDACi) have been FDA approved for myelodysplastic syndromes, evaluation of pan-HDACi in CaP clinical trials as single agents have been ineffective to date largely due to treatment-related toxicity and efficacy as monotherapies. To be able to incorporate HDACi into the treatment of …